{
  "id": "map_1897",
  "title": "UTD\\NCADASIL",
  "specialty": "General",
  "tag": "üìã Gu√≠a Cl√≠nica",
  "node_count": 288,
  "root": {
    "text": "UTD\\NCADASIL",
    "children": [
      {
        "text": "1. Introducci√≥n\\Ny Concepto",
        "children": [
          {
            "text": "1.1. Definici√≥n y\\NClasificaci√≥n",
            "children": [
              {
                "text": "Pertenece al grupo de enfermedades de peque√±o vaso cerebral (CSVD)",
                "children": []
              },
              {
                "text": "Representa el tipo monog√©nico m√°s com√∫n de CSVD",
                "children": []
              },
              {
                "text": "Caracter√≠sticas\\Ndistintivas:",
                "children": [
                  {
                    "text": "Angiopat√≠a no ateroscler√≥tica",
                    "children": []
                  },
                  {
                    "text": "Afectaci√≥n predominante de arterias de mediano y peque√±o calibre",
                    "children": []
                  },
                  {
                    "text": "Compromiso principalmente cerebral",
                    "children": []
                  },
                  {
                    "text": "Herencia autos√≥mica dominante",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "1.2. Caracter√≠sticas\\NPatol√≥gicas Fundamentales",
            "children": [
              {
                "text": "Enfermedad neurol√≥gica con mecanismos patog√©nicos espec√≠ficos",
                "children": []
              },
              {
                "text": "Afectaci√≥n\\Nprincipal:",
                "children": [
                  {
                    "text": "Arterias cerebrales",
                    "children": []
                  },
                  {
                    "text": "Arteriolas",
                    "children": []
                  },
                  {
                    "text": "Vasos de peque√±o calibre",
                    "children": []
                  }
                ]
              },
              {
                "text": "Manifestaciones\\Ncl√≠nicas distintivas:",
                "children": [
                  {
                    "text": "S√≠ntomas neurol√≥gicos progresivos",
                    "children": []
                  },
                  {
                    "text": "Alteraciones estructurales caracter√≠sticas",
                    "children": []
                  }
                ]
              },
              {
                "text": "Diagn√≥stico\\Nbasado en:",
                "children": [
                  {
                    "text": "Historia cl√≠nica y familiar",
                    "children": []
                  },
                  {
                    "text": "Neuroimagen caracter√≠stica (RM)",
                    "children": []
                  },
                  {
                    "text": "Confirmaci√≥n gen√©tica",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "1.3. Evoluci√≥n\\NHist√≥rica",
            "children": [
              {
                "text": "1977: Reporte inicial de demencia multi-infarto hereditaria",
                "children": []
              },
              {
                "text": "1993: Primera definici√≥n y localizaci√≥n cromos√≥mica",
                "children": []
              },
              {
                "text": "1994: Identificaci√≥n del gen NOTCH3",
                "children": []
              },
              {
                "text": "2014-2023: Expansi√≥n del conocimiento gen√©tico y fenot√≠pico",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "## 1. Introducci√≥n y\\NBase Gen√©tica",
        "children": [
          {
            "text": "### 1.1. Fundamentos\\NMoleculares",
            "children": [
              {
                "text": "- CADASIL (Arteriopat√≠a Cerebral Autos√≥mica Dominante con Infartos Subcorticales y Leucoencefalopat√≠a)\\Nes causada por variantes patog√©nicas en el gen NOTCH3.",
                "children": []
              },
              {
                "text": "- El gen NOTCH3 se localiza en el cromosoma 19p13. 2-p13.1 y codifica\\Npara un receptor transmembrana crucial en el desarrollo vascular.",
                "children": []
              },
              {
                "text": "- Se han identificado m√°s de 280 variantes patog√©nicas\\Ndiferentes en pacientes de todo el mundo.",
                "children": []
              }
            ]
          },
          {
            "text": "### 1.2. Caracter√≠sticas de las\\NVariantes Patog√©nicas",
            "children": [
              {
                "text": "- El 95% son variantes de tipo missense que afectan residuos de ciste√≠na.",
                "children": []
              },
              {
                "text": "- Las variantes se concentran principalmente en el extremo N-terminal de la prote√≠na.",
                "children": []
              },
              {
                "text": "- Aproximadamente el 60% se localizan en el ex√≥n 4.",
                "children": []
              },
              {
                "text": "- Cerca del 85% se encuentran en los exones 2 a 6.",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "## 2. Correlaciones\\NFenot√≠picas Principales",
        "children": [
          {
            "text": "### 2.1. Variantes en\\NDominios EGFR 1-6",
            "children": [
              {
                "text": "- Edad de aparici√≥n m√°s temprana de accidentes cerebrovasculares.",
                "children": []
              },
              {
                "text": "- Fenotipo cl√≠nico m√°s severo.",
                "children": []
              },
              {
                "text": "- Mayor volumen de hiperintensidades en sustancia blanca.",
                "children": []
              },
              {
                "text": "- Menor supervivencia en comparaci√≥n con variantes en EGFR 7-34.",
                "children": []
              }
            ]
          },
          {
            "text": "### 2.2. Variantes en\\NOtros Dominios EGFR",
            "children": [
              {
                "text": "- Las variantes en EGFR 7-9 y 18-34 tambi√©n se asocian con enfermedad m√°s grave.",
                "children": []
              },
              {
                "text": "- Se han identificado dominios de alto riesgo adicionales: EGFR 8, 11 y 26.",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "## 3. Sistema de\\NClasificaci√≥n de Riesgo",
        "children": [
          {
            "text": "### 3.1. Categor√≠as de\\NRiesgo por Dominio EGFR",
            "children": [
              {
                "text": "- Alto riesgo: EGFR 1-6, 8, 11 y 26",
                "children": []
              },
              {
                "text": "- Riesgo medio",
                "children": []
              },
              {
                "text": "- Bajo riesgo",
                "children": []
              }
            ]
          },
          {
            "text": "### 3.2. Implicaciones\\NCl√≠nicas",
            "children": [
              {
                "text": "- Las variantes de alto\\Nriesgo muestran:",
                "children": [
                  {
                    "text": "- Progresi√≥n m√°s r√°pida de manifestaciones cl√≠nicas",
                    "children": []
                  },
                  {
                    "text": "- Cambios m√°s severos en neuroimagen",
                    "children": []
                  },
                  {
                    "text": "- Peor pron√≥stico general",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "## 4. Consideraciones\\NEspeciales",
        "children": [
          {
            "text": "### 4.1. Variantes\\NAt√≠picas",
            "children": [
              {
                "text": "- Se han reportado variantes que no afectan residuos de ciste√≠na.",
                "children": []
              },
              {
                "text": "- No existe evidencia experimental que demuestre su patogenicidad.",
                "children": []
              },
              {
                "text": "- Podr√≠an representar polimorfismos raros.",
                "children": []
              }
            ]
          },
          {
            "text": "### 4.2. Implicaciones\\Npara el Diagn√≥stico",
            "children": [
              {
                "text": "- La concentraci√≥n de variantes en exones\\Nespec√≠ficos permite estrategias de cribado dirigido.",
                "children": []
              },
              {
                "text": "- El conocimiento de correlaciones genotipo-fenotipo facilita el pron√≥stico.",
                "children": []
              },
              {
                "text": "- Ayuda en la planificaci√≥n del seguimiento cl√≠nico.",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "## 5. Impacto en el\\NManejo Cl√≠nico",
        "children": [
          {
            "text": "### 5.1. Utilidad\\NPron√≥stica",
            "children": [
              {
                "text": "- Permite anticipar la severidad potencial de la enfermedad.",
                "children": []
              },
              {
                "text": "- Facilita la planificaci√≥n de intervenciones preventivas.",
                "children": []
              },
              {
                "text": "- Ayuda en el asesoramiento gen√©tico.",
                "children": []
              }
            ]
          },
          {
            "text": "### 5.2. Consideraciones\\Npara el Seguimiento",
            "children": [
              {
                "text": "- Necesidad de monitorizaci√≥n m√°s estrecha en pacientes con variantes de alto riesgo.",
                "children": []
              },
              {
                "text": "- Adaptaci√≥n de estrategias preventivas seg√∫n el perfil de riesgo.",
                "children": []
              },
              {
                "text": "- Planificaci√≥n personalizada del seguimiento cl√≠nico y por neuroimagen.",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "2. Epidemiolog√≠a",
        "children": [
          {
            "text": "2.1. Distribuci√≥n\\NGlobal",
            "children": [
              {
                "text": "Distribuci√≥n mundial documentada",
                "children": []
              },
              {
                "text": "Prevalencia\\Nestimada:",
                "children": [
                  {
                    "text": "Global: 2.0-5 casos por 100,000 habitantes",
                    "children": []
                  },
                  {
                    "text": "Canad√°: 1.98 casos por 100,000",
                    "children": []
                  },
                  {
                    "text": "Escocia occidental: 4 casos por 100,000",
                    "children": []
                  },
                  {
                    "text": "Finlandia: 14 casos por 100,000",
                    "children": []
                  }
                ]
              },
              {
                "text": "Posible subestimaci√≥n\\Nsignificativa:",
                "children": [
                  {
                    "text": "Frecuencia de mutaci√≥n predicha: 4.1 a 10.7 portadores por 100,000",
                    "children": []
                  },
                  {
                    "text": "Heterogeneidad en presentaci√≥n cl√≠nica",
                    "children": []
                  },
                  {
                    "text": "Frecuente diagn√≥stico err√≥neo o tard√≠o",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "2.2. Variaciones\\NGeogr√°ficas",
            "children": [
              {
                "text": "Escocia: 4/100,000",
                "children": []
              },
              {
                "text": "Finlandia: 14/100,000",
                "children": []
              },
              {
                "text": "Islas Canarias: Posible subestimaci√≥n",
                "children": []
              },
              {
                "text": "Necesidad de estudios poblacionales amplios",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "3. Fisiopatolog√≠a",
        "children": [
          {
            "text": "3.1. Base Gen√©tica",
            "children": [
              {
                "text": "Gen\\NNOTCH3:",
                "children": [
                  {
                    "text": "Localizaci√≥n: 19p13.2-p13.1",
                    "children": []
                  },
                  {
                    "text": "Funci√≥n: Receptor transmembrana",
                    "children": []
                  },
                  {
                    "text": "Papel en desarrollo vascular",
                    "children": []
                  },
                  {
                    "text": "M√°s de 280 variantes patog√©nicas identificadas",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "3.2. Mecanismos\\NPatog√©nicos",
            "children": [
              {
                "text": "Alteraciones\\NProteicas:",
                "children": [
                  {
                    "text": "Procesamiento anormal del receptor Notch3",
                    "children": []
                  },
                  {
                    "text": "Acumulaci√≥n de dominio extracelular",
                    "children": []
                  },
                  {
                    "text": "Afectaci√≥n de c√©lulas musculares lisas y pericitos",
                    "children": []
                  }
                ]
              },
              {
                "text": "Consecuencias\\NVasculares:",
                "children": [
                  {
                    "text": "Angiopat√≠a no ateroscler√≥tica",
                    "children": []
                  },
                  {
                    "text": "Afectaci√≥n de vasos peque√±os (100-400 micras)",
                    "children": []
                  },
                  {
                    "text": "Alteraci√≥n de barrera hematoencef√°lica",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "4. Manifestaciones\\NCl√≠nicas",
        "children": [
          {
            "text": "4.1. Fenotipo y\\NPresentaci√≥n",
            "children": [
              {
                "text": "Variabilidad fenot√≠pica\\Nsignificativa:",
                "children": [
                  {
                    "text": "Entre familias",
                    "children": []
                  },
                  {
                    "text": "Dentro de mismas familias",
                    "children": []
                  }
                ]
              },
              {
                "text": "Secuencia temporal\\Ncaracter√≠stica:",
                "children": [
                  {
                    "text": "Inicio con migra√±a con aura",
                    "children": []
                  },
                  {
                    "text": "Seguido por eventos isqu√©micos",
                    "children": []
                  },
                  {
                    "text": "Progresi√≥n a deterioro cognitivo",
                    "children": []
                  },
                  {
                    "text": "Desarrollo de demencia",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "4.2. Manifestaciones\\NEspec√≠ficas",
            "children": [
              {
                "text": "4.2.1. Migra√±a\\Ncon Aura",
                "children": [
                  {
                    "text": "Manifestaci√≥n inicial m√°s com√∫n",
                    "children": []
                  },
                  {
                    "text": "Caracter√≠sticas\\Nprincipales:",
                    "children": [
                      {
                        "text": "Edad media de inicio: 30 a√±os",
                        "children": []
                      },
                      {
                        "text": "Precede otros s√≠ntomas por ~10 a√±os",
                        "children": []
                      },
                      {
                        "text": "Prevalencia: 20-40% de pacientes",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Caracter√≠sticas\\Ndistintivas:",
                    "children": [
                      {
                        "text": "5 veces m√°s frecuente que poblaci√≥n general",
                        "children": []
                      },
                      {
                        "text": "Sin diferencia en migra√±a sin aura",
                        "children": []
                      },
                      {
                        "text": "Alta frecuencia de\\Nauras at√≠picas:",
                        "children": [
                          {
                            "text": "Basilar",
                            "children": []
                          },
                          {
                            "text": "Hemipl√©jica",
                            "children": []
                          },
                          {
                            "text": "Prolongada",
                            "children": []
                          },
                          {
                            "text": "Confusi√≥n",
                            "children": []
                          },
                          {
                            "text": "Fiebre asociada",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "Mayor√≠a experimenta m√∫ltiples tipos de aura",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Patrones\\Nespec√≠ficos:",
                    "children": [
                      {
                        "text": "Mayor prevalencia en mujeres",
                        "children": []
                      },
                      {
                        "text": "Posible efecto protector contra ictus",
                        "children": []
                      },
                      {
                        "text": "Tendencia a remisi√≥n tras eventos isqu√©micos",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "4.2.2. Eventos\\NCerebrovasculares",
                "children": [
                  {
                    "text": "AIT y Accidentes\\NCerebrovasculares:",
                    "children": [
                      {
                        "text": "Principal causa de discapacidad y mortalidad",
                        "children": []
                      },
                      {
                        "text": "Caracter√≠sticas:",
                        "children": [
                          {
                            "text": "Seguidos t√≠picamente por ictus isqu√©micos",
                            "children": []
                          },
                          {
                            "text": "Posible confusi√≥n con aura migra√±osa severa",
                            "children": []
                          },
                          {
                            "text": "Frecuencia: hasta 85% de casos sintom√°ticos",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "Cronolog√≠a:",
                        "children": [
                          {
                            "text": "Rango de edad: 20-70 a√±os",
                            "children": []
                          },
                          {
                            "text": "Edad media: 40-50 a√±os",
                            "children": []
                          },
                          {
                            "text": "Predominio en etapas medias de vida",
                            "children": []
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "text": "4.2.3. Factores de\\NRiesgo Vasculares",
                "children": [
                  {
                    "text": "Factores\\Nconvencionales:",
                    "children": [
                      {
                        "text": "Hipertensi√≥n",
                        "children": []
                      },
                      {
                        "text": "Diabetes",
                        "children": []
                      },
                      {
                        "text": "Hiperhomocisteinemia",
                        "children": []
                      },
                      {
                        "text": "Tabaquismo",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Impacto\\Nespec√≠fico:",
                    "children": [
                      {
                        "text": "Aumento de riesgo de ictus isqu√©micos",
                        "children": []
                      },
                      {
                        "text": "Mayor afectaci√≥n cl√≠nica en pacientes con factores de riesgo",
                        "children": []
                      },
                      {
                        "text": "Asociaci√≥n con inicio m√°s temprano",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Mecanismos:",
                    "children": [
                      {
                        "text": "Oclusi√≥n de arterias perforantes",
                        "children": []
                      },
                      {
                        "text": "Agravamiento de d√©ficits existentes",
                        "children": []
                      },
                      {
                        "text": "Aceleraci√≥n de progresi√≥n",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "4.2.4. Deterioro\\NCognitivo y Demencia",
                "children": [
                  {
                    "text": "Caracter√≠sticas\\Nprincipales:",
                    "children": [
                      {
                        "text": "Segunda manifestaci√≥n m√°s com√∫n",
                        "children": []
                      },
                      {
                        "text": "Progresi√≥n escalonada tras eventos isqu√©micos",
                        "children": []
                      },
                      {
                        "text": "Desarrollo frecuente de demencia",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Patrones\\Ncognitivos:",
                    "children": [
                      {
                        "text": "Deterioro ejecutivo temprano",
                        "children": []
                      },
                      {
                        "text": "Afectaci√≥n predominante <60 a√±os",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Perfil diferente\\Nseg√∫n edad:",
                    "children": [
                      {
                        "text": "Menores de 60: principalmente funci√≥n ejecutiva",
                        "children": []
                      },
                      {
                        "text": "Mayores de 60: m√∫ltiples dominios afectados",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Evoluci√≥n:",
                    "children": [
                      {
                        "text": "Un tercio desarrolla demencia en etapas medias",
                        "children": []
                      },
                      {
                        "text": "Aproximadamente 40% demenciados >60 a√±os",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Patr√≥n diferencial\\Nrespecto a Alzheimer:",
                    "children": [
                      {
                        "text": "Preservaci√≥n relativa de memoria epis√≥dica",
                        "children": []
                      },
                      {
                        "text": "Proceso de codificaci√≥n conservado",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "4.2.5. Alteraciones\\NPsiqui√°tricas",
                "children": [
                  {
                    "text": "Prevalencia:",
                    "children": [
                      {
                        "text": "20-41% de pacientes",
                        "children": []
                      },
                      {
                        "text": "Posible manifestaci√≥n inicial (15% casos)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Manifestaciones\\Nprincipales:",
                    "children": [
                      {
                        "text": "Depresi√≥n (m√°s com√∫n)",
                        "children": []
                      },
                      {
                        "text": "Trastornos del estado de √°nimo",
                        "children": []
                      },
                      {
                        "text": "Depresi√≥n mayor (21%)",
                        "children": []
                      },
                      {
                        "text": "Apat√≠a (41%)",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Otros trastornos:",
                    "children": [
                      {
                        "text": "Trastornos de ajuste",
                        "children": []
                      },
                      {
                        "text": "Trastornos bipolares",
                        "children": []
                      },
                      {
                        "text": "Trastornos de ansiedad",
                        "children": []
                      },
                      {
                        "text": "Psicosis",
                        "children": []
                      },
                      {
                        "text": "Man√≠a",
                        "children": []
                      },
                      {
                        "text": "Distimia",
                        "children": []
                      },
                      {
                        "text": "Ideaci√≥n suicida",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "Comorbilidades:",
                    "children": [
                      {
                        "text": "Trastornos de personalidad",
                        "children": []
                      },
                      {
                        "text": "Adicciones",
                        "children": []
                      },
                      {
                        "text": "Alucinaciones",
                        "children": []
                      },
                      {
                        "text": "Esquizofrenia",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "4.2.6. Trastornos del\\NMovimiento y Parkinsonismo",
                "children": [
                  {
                    "text": "Parkinsonismo:",
                    "children": [
                      {
                        "text": "Hasta 6% de pacientes",
                        "children": []
                      },
                      {
                        "text": "Asociaci√≥n con mutaciones NOTCH3",
                        "children": []
                      },
                      {
                        "text": "Presentaci√≥n\\Nvariable con:",
                        "children": [
                          {
                            "text": "Parkinsonismo vascular",
                            "children": []
                          },
                          {
                            "text": "Ataxia progresiva",
                            "children": []
                          },
                          {
                            "text": "Par√°lisis supranuclear progresiva",
                            "children": []
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "text": "Otros trastornos:",
                    "children": [
                      {
                        "text": "Atrofia de sistemas m√∫ltiples",
                        "children": []
                      },
                      {
                        "text": "Trastornos hipercin√©ticos",
                        "children": []
                      },
                      {
                        "text": "Corea",
                        "children": []
                      },
                      {
                        "text": "Diston√≠a",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "5. Diagn√≥stico",
        "children": [
          {
            "text": "5.1. Criterios\\NDiagn√≥sticos",
            "children": [
              {
                "text": "Confirmaci√≥n\\NGen√©tica:",
                "children": [
                  {
                    "text": "An√°lisis de NOTCH3",
                    "children": []
                  },
                  {
                    "text": "Identificaci√≥n de variantes patog√©nicas",
                    "children": []
                  }
                ]
              },
              {
                "text": "Biopsia\\NCut√°nea:",
                "children": [
                  {
                    "text": "Material osmiof√≠lico granular",
                    "children": []
                  },
                  {
                    "text": "Dep√≥sitos caracter√≠sticos",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "5.2. Neuroimagen",
            "children": [
              {
                "text": "Hallazgos\\Nen RM:",
                "children": [
                  {
                    "text": "Hiperintensidades temporales anteriores",
                    "children": []
                  },
                  {
                    "text": "Lesiones lacunares subcorticales",
                    "children": []
                  },
                  {
                    "text": "Microsangrados cerebrales",
                    "children": []
                  },
                  {
                    "text": "Atrofia cerebral progresiva",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "5.3. Diagn√≥stico\\NDiferencial",
            "children": [
              {
                "text": "Enfermedad de peque√±o vaso espor√°dica",
                "children": []
              },
              {
                "text": "Esclerosis m√∫ltiple",
                "children": []
              },
              {
                "text": "Vasculitis primaria del SNC",
                "children": []
              },
              {
                "text": "Enfermedad de Fabry",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "6. Tratamiento",
        "children": [
          {
            "text": "6.1. Manejo Agudo",
            "children": [
              {
                "text": "Tratamiento de ictus seg√∫n protocolos",
                "children": []
              },
              {
                "text": "Consideraciones especiales en trombolisis",
                "children": []
              },
              {
                "text": "Manejo de complicaciones agudas",
                "children": []
              }
            ]
          },
          {
            "text": "6.2. Prevenci√≥n",
            "children": [
              {
                "text": "Control de Factores\\Nde Riesgo:",
                "children": [
                  {
                    "text": "Hipertensi√≥n arterial",
                    "children": []
                  },
                  {
                    "text": "Diabetes",
                    "children": []
                  },
                  {
                    "text": "Dislipemia",
                    "children": []
                  },
                  {
                    "text": "Tabaquismo",
                    "children": []
                  }
                ]
              },
              {
                "text": "Terapia\\NAntitromb√≥tica:",
                "children": [
                  {
                    "text": "Aspirina dosis baja",
                    "children": []
                  },
                  {
                    "text": "Evitar anticoagulaci√≥n",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "6.3. Tratamiento\\NSintom√°tico",
            "children": [
              {
                "text": "Manejo de migra√±a",
                "children": []
              },
              {
                "text": "Tratamiento de depresi√≥n",
                "children": []
              },
              {
                "text": "Control de s√≠ntomas cognitivos",
                "children": []
              },
              {
                "text": "Manejo de crisis epil√©pticas",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "7. Pron√≥stico y\\NSeguimiento",
        "children": [
          {
            "text": "7.1. Curso Cl√≠nico",
            "children": [
              {
                "text": "Progresi√≥n variable",
                "children": []
              },
              {
                "text": "Deterioro escalonado frecuente",
                "children": []
              },
              {
                "text": "Supervivencia media:",
                "children": [
                  {
                    "text": "Hombres: 65 a√±os",
                    "children": []
                  },
                  {
                    "text": "Mujeres: 71 a√±os",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "7.2. Factores\\NPron√≥sticos",
            "children": [
              {
                "text": "Alteraci√≥n de la marcha",
                "children": []
              },
              {
                "text": "Tabaquismo activo",
                "children": []
              },
              {
                "text": "Historia de ictus",
                "children": []
              },
              {
                "text": "Hallazgos en neuroimagen",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "8. Aspectos Gen√©ticos\\Ny Familiares",
        "children": [
          {
            "text": "8.1. Consejo\\NGen√©tico",
            "children": [
              {
                "text": "Herencia autos√≥mica dominante",
                "children": []
              },
              {
                "text": "Penetrancia variable",
                "children": []
              },
              {
                "text": "Expresividad variable",
                "children": []
              },
              {
                "text": "Consideraciones reproductivas",
                "children": []
              }
            ]
          },
          {
            "text": "8.2. Cribado\\NFamiliar",
            "children": [
              {
                "text": "Asesoramiento previo obligatorio",
                "children": []
              },
              {
                "text": "No realizar pruebas en ni√±os asintom√°ticos",
                "children": []
              },
              {
                "text": "Seguimiento estructurado de portadores",
                "children": []
              },
              {
                "text": "Apoyo psicosocial",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "9. Perspectivas\\NFuturas",
        "children": [
          {
            "text": "9.1. Investigaci√≥n",
            "children": [
              {
                "text": "Desarrollo de terapias modificadoras",
                "children": []
              },
              {
                "text": "Identificaci√≥n de biomarcadores",
                "children": []
              },
              {
                "text": "Estudios de historia natural",
                "children": []
              },
              {
                "text": "Registros multic√©ntricos",
                "children": []
              }
            ]
          },
          {
            "text": "9.2. Desaf√≠os\\NPendientes",
            "children": [
              {
                "text": "Tratamiento espec√≠fico",
                "children": []
              },
              {
                "text": "Prevenci√≥n de progresi√≥n",
                "children": []
              },
              {
                "text": "Mejora en diagn√≥stico temprano",
                "children": []
              },
              {
                "text": "Optimizaci√≥n de seguimiento",
                "children": []
              }
            ]
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1673",
      "title": "DAPA-CKD (2020)\\NDapagliflozin And Prevention\\Nof Adverse outcomes in CKD\\N\\N‚≠ê iSGLT2 protege ri√±√≥n\\NINCLUSO SIN DIABETES\\N(Extiende beneficio a ERC no-DM)"
    },
    {
      "id": "map_1674",
      "title": "CREDENCE (2019)\\NCanagliflozin and Renal Events in Diabetes\\N\\nCanagliflozina reduce progresion ERC\\ny eventos CV en DM2 con nefropatia\\nNNTH 22 para outcome renal"
    },
    {
      "id": "map_1688",
      "title": "CLARITY-AD (2022)\\NLecanemab in Early Alzheimers Disease\\N\\nLecanemab reduce deterioro cognitivo 27%\\nen EA temprana con amiloide confirmado\\nPrimer anti-amiloide con beneficio clinico claro"
    },
    {
      "id": "map_1689",
      "title": "SPRINTT (2021)\\NSarcopenia and Physical\\NFragility in Older People:\\NMulti-component Treatment\\N\\n‚≠ê Ejercicio + nutrici√≥n reduce\\ndiscapacidad en fragilidad f√≠sica\\ncon sarcopenia"
    },
    {
      "id": "map_1805",
      "title": "Deterioro Cognitivo Vascular (DCV)\\Ny Demencia Vascular"
    }
  ],
  "source_file": "CADASIL-2025.smmx",
  "created": "2026-02-07T15:43:05.799620"
}